Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A special report on living with cancer
The goal of developing this type of test “is to safely prevent unnecessary surgeries,” said lead investigator Yuri Nikiforov, MD, PhD.
New drug targets RET mutations in multiple cancer types.
This group is more likely to develop several cancers, especially breast cancer, melanoma and non-melanoma skin cancers.
A new therapy, BLU-667, shows broad antitumor activity against cancers with a variety of RET alterations.
Thyroid tumors may be more susceptible to treatment with precisely targeted radiation known as stereotactic body radiation therapy.
LOXO-292 demonstrates durable antitumor activity in people with lung, thyroid and other cancers with RET mutations.
Tafinlar and Mekinist approved for a third cancer with specific gene mutation.
BLU-667 shrinks thyroid and lung cancers with RET gene alterations.
Looking harder for cancer can lead to a self-fulfilling increase in cancer diagnosis.
Cancer Health Basics offer need-to-know health facts on a variety of cancer topics from a general cancer 101 to specific cancer types and trea...
New recommendations warn folks not to get tested if they don’t have symptoms of thyroid problems.
The “Flip or Flop” cohost spoke out about his battle with the two conditions to raise awareness and demonstrate that both are curable.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.